Does nivolumab dose affect survival in clinical trials?
Clinical trials show mixed evidence on nivolumab (Opdivo) dose and overall survival (OS). Flat dosing at 240 mg every 2 weeks or 480 mg every 4 weeks—regardless of body weight—yielded similar OS rates to higher weight-based doses (3 mg/kg) in non-small cell lung cancer (NSCLC) and other cancers. A 2017 phase 3 CheckMate 017/057 pooled analysis found median OS of 9.7 months at 3 mg/kg Q2W versus 11.1 months at fixed 240 mg Q2W, with no statistical difference (HR 0.92, 95% CI 0.80-1.05).[1][2]
What do dose-response studies reveal?
Early trials tested a range from 0.1 to 10 mg/kg. Objective response rates (ORR) increased with dose up to 3 mg/kg in melanoma and NSCLC, plateauing beyond that, suggesting no added survival benefit from higher doses.[3] The CheckMate 067 trial in melanoma confirmed equivalent OS across 1 mg/kg, 3 mg/kg, and combination regimens with ipilimumab.[4] No consistent dose-survival correlation emerges above 3 mg/kg; pharmacokinetics indicate target saturation at these levels.
How does this compare across cancer types?
- NSCLC: Flat-dose OS matches weight-based in CheckMate 227 (HR 1.02).[2]
- Melanoma: Dose escalation beyond 3 mg/kg showed no OS gain in phase 1/2 data.[3]
- Renal cell carcinoma: CheckMate 025 used fixed 240 mg, achieving median OS of 25.5 months without dose optimization signals.[5]
Hodgkin lymphoma trials used even lower doses (e.g., 240 mg), correlating with high response but limited OS readouts due to early censoring.[6]
Why switch to flat dosing if survival is similar?
Flat dosing simplifies administration and cuts costs over weight-based regimens, approved by FDA in 2018 based on pharmacokinetic bridging studies showing equivalent exposure.[1][7] No survival detriment observed; some data hint at slightly better tolerability with flat doses due to lower peak levels in lighter patients.
Are there risks or subgroups where dose matters?
Higher doses (>10 mg/kg) increase grade 3-4 immune-related adverse events without OS upside.[3] Obese patients on flat dosing maintain efficacy, avoiding underdosing from ideal body weight caps.[8] No strong evidence for dose adjustments in elderly or low-performance status patients, though real-world data is sparse.
Sources
[1]: FDA Label for Opdivo
[2]: CheckMate 017/057 Pooled Analysis, Lancet Oncol 2018
[3]: Nivolumab Dose Escalation, J Clin Oncol 2014
[4]: CheckMate 067, NEJM 2015
[5]: CheckMate 025, NEJM 2015
[6]: CheckMate 205, Blood 2018
[7]: BMS Flat-Dose PK Study, Clin Cancer Res 2017
[8]: Obesity and ICI Dosing, J Immunother Cancer 2020